We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Wins Expanded Xgeva Approval for GCTB
Amgen Wins Expanded Xgeva Approval for GCTB
June 21, 2013
The FDA June 13 approved an additional indication for Amgen’s Xgeva to treat adults and some adolescents with giant cell tumor of the bone (GCTB), which is rare and usually non-cancerous.